Published in FASEB J on April 05, 2007
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Anchoring junctions as drug targets: role in contraceptive development. Pharmacol Rev (2008) 1.76
Minireview: nuclear receptors and breast cancer. Mol Endocrinol (2008) 1.58
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol (2012) 1.44
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20
Integration of progesterone receptor action with rapid signaling events in breast cancer models. J Steroid Biochem Mol Biol (2007) 0.94
Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer (2011) 0.92
Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med (2014) 0.92
Androgens in pregnancy: roles in parturition. Hum Reprod Update (2014) 0.89
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells. Breast Cancer Res (2008) 0.89
Gender-medicine aspects in allergology. Allergy (2008) 0.88
Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases. Cancer Prev Res (Phila) (2008) 0.85
Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Mol Cell Endocrinol (2011) 0.83
Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors. Indian J Med Res (2012) 0.81
Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol (2016) 0.78
Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner. J Biol Chem (2014) 0.78
Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer (2016) 0.77
The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care (Basel) (2008) 0.77
Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers. Br J Cancer (2015) 0.75
Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Res (2015) 0.75
Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids. PLoS One (2016) 0.75
Effects of maternal dietary exposure to cadmium during pregnancy on mammary cancer risk among female offspring. J Carcinog (2013) 0.75
AR Signaling in Breast Cancer. Cancers (Basel) (2017) 0.75
Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer. J Breast Health (2013) (2014) 0.75
Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech (2016) 0.75
Food insufficiency is associated with high-risk sexual behavior among women in Botswana and Swaziland. PLoS Med (2007) 4.48
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun (2013) 2.11
Variable stoichiometry of the TatA component of the twin-arginine protein transport system observed by in vivo single-molecule imaging. Proc Natl Acad Sci U S A (2008) 2.09
Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
Role of the Escherichia coli Tat pathway in outer membrane integrity. Mol Microbiol (2003) 1.96
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer (2007) 1.94
Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev (2012) 1.84
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc (2005) 1.76
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 1.73
Exploring the patterns of use and the feasibility of using cellular phones for clinic appointment reminders and adherence messages in an antiretroviral treatment clinic, Durban, South Africa. AIDS Patient Care STDS (2010) 1.73
Coordinating assembly and export of complex bacterial proteins. EMBO J (2004) 1.73
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst (2013) 1.70
Social cognition and face processing in schizophrenia. Br J Psychiatry (2004) 1.67
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer (2012) 1.60
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Conserved network of proteins essential for bacterial viability. J Bacteriol (2009) 1.48
Behaviour of topological marker proteins targeted to the Tat protein transport pathway. Mol Microbiol (2002) 1.47
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer (2011) 1.46
Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem (2007) 1.42
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer (2016) 1.39
Phosphorylation of the Pseudomonas aeruginosa response regulator AlgR is essential for type IV fimbria-mediated twitching motility. J Bacteriol (2002) 1.37
The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol Endocrinol (2008) 1.32
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev (2011) 1.31
Changes in dietary intake after diagnosis of breast cancer. J Am Diet Assoc (2004) 1.30
Structural analysis of substrate binding by the TatBC component of the twin-arginine protein transport system. Proc Natl Acad Sci U S A (2009) 1.29
Stable-isotope labeling with amino acids in nematodes. Nat Methods (2011) 1.28
The activation function-1 domain of Nur77/NR4A1 mediates trans-activation, cell specificity, and coactivator recruitment. J Biol Chem (2002) 1.25
Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev (2011) 1.22
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res (2007) 1.20
Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res (2004) 1.20
Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.20
Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat (2008) 1.19
Aprataxin forms a discrete branch in the HIT (histidine triad) superfamily of proteins with both DNA/RNA binding and nucleotide hydrolase activities. J Biol Chem (2006) 1.19
Probing the specificity of binding to the major nuclear localization sequence-binding site of importin-alpha using oriented peptide library screening. J Biol Chem (2010) 1.18
Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt". Int J Cancer (2010) 1.18
Cysteine scanning mutagenesis and disulfide mapping studies of the TatA component of the bacterial twin arginine translocase. J Biol Chem (2007) 1.16
Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res (2004) 1.16
Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer (2007) 1.15
Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.15
A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res (2002) 1.14
Cysteine-scanning mutagenesis and disulfide mapping studies of the conserved domain of the twin-arginine translocase TatB component. J Biol Chem (2006) 1.12
Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev (2010) 1.12
The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine. J Biol Chem (2003) 1.12
Subunit composition and in vivo substrate-binding characteristics of Escherichia coli Tat protein complexes expressed at native levels. FEBS J (2006) 1.09
Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiol Biomarkers Prev (2010) 1.07
The entire N-terminal half of TatC is involved in twin-arginine precursor binding. Biochemistry (2007) 1.07
Structural diversity in twin-arginine signal peptide-binding proteins. Proc Natl Acad Sci U S A (2007) 1.07
Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol (2009) 1.06
Degenerative disc disease treated with combined anterior and posterior arthrodesis and posterior instrumentation. Spine (Phila Pa 1976) (2002) 1.06
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res (2011) 1.05
Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. Nucleic Acids Res (2003) 1.03
Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem Biol (2009) 1.03
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res (2005) 1.02
Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res (2003) 1.02
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep (2010) 1.02
Circulating microRNAs: macro-utility as markers of prostate cancer? Endocr Relat Cancer (2012) 1.02
Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol (2009) 1.01
Emotional memory in schizophrenia. Neuropsychologia (2006) 1.00
Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate (2005) 1.00
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
Truncation analysis of TatA and TatB defines the minimal functional units required for protein translocation. J Bacteriol (2002) 0.99